Does Finasteride Increase Prostate Cancer Risk? Studies and PSA Changes
Finasteride (Propecia) is one of the most established medicines used for male pattern hair loss. A common question during long-term treatment is whether it increases prostate cancer risk.
The major studies are broadly reassuring: there is no evidence that finasteride increases prostate cancer mortality, and it has been associated with fewer overall prostate cancer diagnoses.
Finasteride does, however, lower prostate-specific antigen (PSA). Anyone taking it should tell the clinician interpreting a PSA test so that the result can be assessed in context.
Key point: the trend may matter more than a single result. Pay particular attention when PSA reaches a stable low point on finasteride and then rises repeatedly. Do not use a simple doubling calculation to rule out disease, and do not stop treatment without medical advice.
What did the major finasteride prostate cancer trial find?
The landmark Prostate Cancer Prevention Trial (PCPT) was supported by the US National Cancer Institute (NCI). It randomly assigned 18,882 men aged 55 or older to finasteride 5 mg daily or placebo.
The original analysis found an approximately 25% relative reduction in prostate cancer risk. With an additional year of diagnoses included, prostate cancer was diagnosed in 10.5% of the finasteride group and 14.9% of the placebo group, a relative reduction of about 30%.
These findings do not support an increase in overall prostate cancer diagnoses. However, the PCPT studied finasteride 5 mg in men aged 55 or older. It should not be interpreted as a recommendation to use finasteride 1 mg for cancer prevention in all men with hair loss.
Why was there concern about high-grade prostate cancer?
The initial PCPT report found fewer total prostate cancers in the finasteride group but a slightly higher proportion classified as higher Gleason grade. That result understandably raised concern.
Later analyses suggested that detection bias may explain at least part of the difference:
- Finasteride reduces prostate volume.
- A tumour of the same size may be more likely to be sampled in a smaller prostate.
- PSA testing, digital rectal examination, and biopsy may become more sensitive for cancer detection.
Most importantly, the concern did not translate into higher mortality in long-term follow-up. NCI data with a median follow-up of 18.4 years found no statistically significant difference in prostate cancer mortality between the finasteride and placebo groups.
It is therefore incomplete to say simply that “finasteride causes high-grade prostate cancer.” The trial initially detected a higher proportion of high-grade disease, detection effects may explain part of it, and long-term mortality did not increase.
Finasteride lowers PSA: an important issue for long-term users
PSA is one of the clinical markers used when assessing prostate conditions and screening for prostate cancer. By inhibiting 5-alpha reductase and lowering DHT, finasteride also reduces prostate volume and PSA.
After continued use of a 5-alpha-reductase inhibitor, PSA commonly falls by about 50%. Clinicians often use an approximate doubling adjustment, but they still interpret the result together with treatment duration and other clinical information.
This is relevant even at the 1 mg dose used for male pattern hair loss. In a randomised trial of men aged 40–60 taking finasteride 1 mg for 48 weeks, the median PSA decline was 40% in those aged 40–49 and 50% in those aged 50–60.
For broader treatment context, read about finasteride side effects in hair loss and using Propecia after age 46.
A simple example of the approximate PSA adjustment
Suppose a man’s PSA was 2.0 ng/mL before treatment and measures 1.0 ng/mL after long-term finasteride use. If the clinician does not know about the medicine, the apparent value may understate the pre-treatment baseline.
| Situation | Measured PSA | Interpretation |
|---|---|---|
| Before finasteride | 2.0 ng/mL | One component of the personal baseline |
| Example during long-term use | 1.0 ng/mL | Finasteride may have lowered the result |
| Common adjustment concept | 1.0 × 2 ≈ 2.0 ng/mL | A clinical reference only, not a stand-alone diagnosis |
The actual interpretation cannot rely on “multiply by two” alone. Duration of treatment, age, the serial PSA pattern, prostate size, family history, adherence, and other clinical findings all matter.
Why the PSA trend from its lowest point matters
A fall in PSA after starting finasteride is an expected drug effect and is not itself a warning sign.
What deserves attention is a PSA that first falls to a stable low point, or nadir, and then rises repeatedly. The FDA prescribing information states that any confirmed rise from the lowest PSA reached while taking Propecia may warrant evaluation, even when the value remains within the usual range for men not taking the medicine.
For long-term users, serial change can therefore be more informative than one isolated result. A urologist should assess a sustained increase.
Should men using finasteride for hair loss stop because of cancer concerns?
Current evidence does not support stopping finasteride solely out of fear of prostate cancer. The practical step is to disclose the medicine, dose, and duration whenever PSA is measured, especially as you reach an age when prostate assessment becomes relevant.
The prescribing clinician or urologist can then interpret the absolute result and its trajectory correctly. If you are concerned about sexual effects, see our review of finasteride sexual side effects and MDL 2331.
For hair transplant patients, surgery replaces hair that has already been lost, while medical treatment may help maintain susceptible native hair. Learn more about medication after hair transplantation.
Taiwan Hair Clinic summary
- Finasteride has not been shown to increase prostate cancer mortality.
- Large trials found fewer overall prostate cancer diagnoses with finasteride.
- Finasteride lowers PSA, so current or recent use must be disclosed before testing.
- Long-term follow-up should consider the PSA trend, especially a confirmed rise from the treatment nadir.
This article provides general medical education and does not replace individual diagnosis. Seek urological assessment if PSA is abnormal or continues to rise, or if you have a family history of prostate cancer.
References
- US National Cancer Institute: PCPT questions and answers
- NCI Prostate Cancer Prevention (PDQ)
- Thompson IM Jr, et al. Long-term survival of participants in the PCPT. N Engl J Med. 2013.
- D’Amico AV, et al. Effect of finasteride 1 mg on serum PSA in androgenic alopecia. Lancet Oncology. 2007.
- US FDA: Propecia (finasteride 1 mg) prescribing information
Does finasteride increase prostate cancer risk? +
The PCPT did not show an increase in overall prostate cancer diagnoses with finasteride; diagnoses were lower. Long-term follow-up also found no statistically significant increase in prostate cancer mortality.
Does finasteride increase high-grade prostate cancer? +
The original PCPT analysis found a higher proportion of high-grade cancers, but later analyses suggested that prostate shrinkage and improved detection may explain at least part of this finding. Long-term mortality did not increase.
How much can finasteride lower PSA? +
PSA often falls by about 50% after continued use of a 5-alpha-reductase inhibitor. In a trial of finasteride 1 mg, the median decline at 48 weeks was 40% in men aged 40–49 and 50% in men aged 50–60, with individual variation.
Should every PSA result be doubled while taking finasteride? +
Doubling is a common clinical adjustment concept, not a universal formula. Duration of use, age, baseline and serial PSA, prostate size, family history, and other clinical factors still matter.
Does a rise in PSA after it reaches a low point matter? +
Yes. A confirmed rise from the lowest PSA reached on treatment deserves medical assessment even if the absolute value still appears low.
Should I stop finasteride because I am worried about prostate cancer? +
Do not stop it on your own. Discuss your individual benefits, risks, and alternatives with the prescribing clinician, and always disclose current or recent finasteride use before PSA testing.
Related articles
This article has been reviewed and medically approved by Dr. Wen-Yi Wu
Dr. Wen-Yi Wu｜Director, Mong Hair Clinic
- ● Fellow of ISHRS (FISHRS)
- ● ABHRS Board-Certified Hair Restoration Surgeon
- ● President of TSHRS (Taiwan Society of Hair Restoration Surgery)